Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma 2Liposarcoma 2Hematologic Neoplasms 2Gliosarcoma 2

Interventions

varlilumab 1Vincristine 1Tomography, X-Ray Computed 1Rituximab 1Prednisone 1Nivolumab 1Interferons 1Immunoglobulin G 1Etoposide 1Echocardiography 1EPOCH protocol 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Caves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphomatoid Granulomatosis × Immunoglobulin G × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡